A TLR7 agonist enhances the anti-tumour efficacy of obinutuzumab through an NK cell/CD4 dependent mechanism in a murine lymphoma model. (July 2016) - Cheadle, E.; Lipowska-Bhalla, G.; Fagnano, E.; Klein, C.; Dovedi, S.; Honeychurch, J.; Illidge, T.